Claim Amendments

1-45 (canceled)

46 (currently amended): A method of determining whether a drug or compound is effective against *Mycobacterium tuberculosis* comprising:

(a) transforming, into a mycobacterium, a vector construct comprising ~~the~~a nucleotide sequence of ~~the~~a *Mycobacterium tuberculosis* iniB promoter inserted into a plasmid ~~into a mycobacterium~~;

(b) culturing the mycobacterium:;

(c) treating the cultured ~~cells~~mycobacterium with the drug; and

(d) measuring induction of the iniB promoter, the presence of induction indicating the drug is effective against *Mycobacterium tuberculosis*.

47 (withdrawn)

48 (previously added): The method of claim 46, wherein the mycobacterium is selected from the group consisting of *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium smegmatis*, *Mycobacterium bovis BCG*, *Mycobacterium leprae*, *Mycobacterium africanium*, and *Mycobacterium intracellulare*.

49 (previously added): The method of claim 46, wherein the induction of the iniB promoter causes the expression of a reporter gene.

50 (previously added): The method of claim 49, wherein the reporter gene is selected from the group consisting of lacZ and luciferase.

51 (currently amended): ~~the~~The method of claim 46, wherein the drug or compound is effective against the biosynthesis of the *Mycobacterium tuberculosis* cell wall.

52 (new): The method of claim 46, wherein the nucleotide sequence of the iniB promoter comprises SEQ ID NO:1 and nucleotides 1-159 of SEQ ID NO:2.